Gastroenterology Research and Practice / 2017 / Article / Tab 1

Research Article

Safety and Efficacy of Exclusive Enteral Nutrition for Percutaneously Undrainable Abdominal Abscesses in Crohn’s Disease

Table 1

Demographic and clinical characteristics of CD patients with percutaneously undrainable abscesses by the treatment group.

CharacteristicsEEN group ()Non-EEN group ()

Gender, n (male/female)32/2215/140.509
Age at onset of abscess (y), median (range)32.8 (17–51)37.1 (17–60)0.094
Disease duration (y), median (range)4.3 (0.16–30)5.5 (0.1–20)0.274
Previous abdominal surgery, n (%)11 (20.4)8 (27.6)0.456
Montreal classification of age, n (%)0.526
 A1 (<16 years)0 (0)0 (0)
 A2 (17–40 years)39 (72.2)19 (65.5)
 A3 (>40 years)15 (27.8)10 (34.5)
Montreal classification of disease location, n (%)1.000
 L1 (ileal)18 (33.3)10 (34.5)
 L2 (colonic)2 (3.7)1 (3.4)
 L3 (ileocolonic)34 (63.0)18 (62.1)
Abscess location, n (%)0.574
 Right lower quadrant24 (44.4)13 (44.8)
 Pelvis18 (33.3)7 (24.1)
 Others12 (22.2)9 (31.0)
Multiple abscesses, n (%)8 (14.8)7 (24.1)0.293
Abscess diameter > 3 cm, n (%)11 (11.1)11 (24.1)0.084
Fistula, n (%)31 (57.4)11 (37.9)0.091
Perianal lesion, n (%)7 (13.0)7 (24.1)0.227
Steroids at diagnosis, n (%)18 (33.3)14 (48.3)0.182
AZA/6-MP at diagnosis, n (%)20 (37.0)14 (48.3)0.321
Infliximab at diagnosis, n (%)7 (13.0)3 (10.3)1.000
Laboratory indices
 White blood cell (×109/L), mean, (range)8.8 (3.6–15)7.1 (2.7–11.6)0.012
 Hemoglobin (g/L), mean (range)11.8 (6.1–15.8)10.9 (6.6–14.1)0.366
 ESR (mm/h), mean (range)36.7 (2–92)33.3 (2–96)0.574
 C-reactive protein (mg/L), mean (range)56.4 (3.9–202.4)32.6 (0.4–159)0.029
 Albumin (g/L), mean (range)32.5 (19.5–41.1)30.8 (17–40.3)0.216

ESR: erythrocyte sedimentation rate; EEN: exclusive enteral nutrition; AZA: azathioprine; 6-MP: mercaptopurine.

Article of the Year Award: Outstanding research contributions of 2020, as selected by our Chief Editors. Read the winning articles.